Status:
COMPLETED
Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
Novartis Pharmaceuticals
Conditions:
Myeloproliferative Neoplasms (MPN)
Polycythemia Vera (PV)
Eligibility:
All Genders
Phase:
NA
Brief Summary
This study involves screening for portal vein thrombosis and portal hypertension in patients with Philadelphia negative myeloproliferative neoplasms (MPNs). These include polycythemia vera (PV), essen...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- One of the three classical Philadelphia negative myeloproliferative neoplasms (polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF)) diagnosed according to WHO or International working group-Myelofibrosis research and treatment (IWG-MRT) criteria
- Palpable spleen length greater than 5 cm below the costal margin in MF (including primary MF or post-polycythemia vera MF (PPV-MF) post-polycythemia vera ET (PPV-ET)) or palpable spleen of any size in patients with PV or ET.
- Ability to understand and willing to sign a written consent form.
- Age 18 years or older at time of consent.
- Exclusion criteria:
- Known history of portal vein thrombosis
- Known history of Budd-chairi syndrome
- Known history of oesophageal varices
- Known history of cirrhosis from any cause
- Known history of active bleeding
Exclusion
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 11 2019
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT01816256
Start Date
May 1 2013
End Date
March 11 2019
Last Update
July 21 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
2
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9